非小细胞肺癌适形放射治疗中急性放射性食管炎影响因素的研究

目的 探讨接受三维适形放疗(3D-CRT)的非小细胞肺癌(NSCLC)患者发生≥2级急性放射性食管炎(ARE)的影响因素。方法 回顾102例接受3D-CRT的NSCLC患者的临床资料及三维计划资料,采用RTOG分级标准,评价患者自放疗开始3个月内≥2级的ARE。分析临床因素和三维计划的剂量体积参数。结果 发生2级ARE19例,3级15例,未出现更严重的ARE。非同步化疗组多因素回归分析显示,食管V55(OR=1.170,P<0.05)为≥2级ARE发生的惟一影响因素,食管V55的ROC曲线下面积为0.870(95%CI: 0.782~0.957,P＜0.05),界值为16.0。同步化疗组多因素回归分析显示,食管V₃₅(OR=1.125,P<0.05)和同步化疗方案(OR=39.740,P<0.05)是≥2级ARE发生的影响因素,食管V₃₅的ROC曲线下面积为0.782(95%CI: 0.636~0.927,P<0.05),界值为23.75。长春瑞滨+顺铂(NP)同步化疗方案的≥2级ARE发生率明显低于其他方案(33.3% ∶66.7%)。结论 非同步化疗患者,食管V55是≥2级ARE的影响因素。同步化疗患者,食管V₃₅和同步化疗方案是≥2级ARE的影响因素。同步NP方案≥2级ARE发生率较低。

Clinical and dosimetric risk factors of acute radiation esophagitis in non-small cell lung cancer patients treated with three-dimensional conformal radiotherapy

Objective To analyze the clinical and dosimetric risk factors for acute radiation esophagitis (ARE) in non-small cell lung cancer (NSCLC) patients treated with three-dimensional conformal radiotherapy (3D-CRT),and to find significant risk factors for clinical therapy.Methods A total of 102 NSCLC patients treated with 3D-CRT were retrospectively analyzed.ARE was scored according to the Radiation Therapy Oncology Group (RTOG) criteria with grade 2 or worse.Patients were divided into non-concurrent chemoradiotherapy group and concurrent chemoradiotherapy group.The clinical and dosimetric factors associated with grade 2 or worse ARE were analyzed using univariate logistic regression,multivariate logistic analysis and receiver operating characteristic ( ROC ) curve.Results There were no grade 4 or5 ARE observed in the 102 patients.Nineteen developed grade 2,15 developed grade 3.In nonconcurrent chemoradiotherapy group,multivariate analysis showed that V55 was the only risk factor of grade 2/3 ARE.For ROC curve analysis,the cut-off point of V55 was 16.0 while the area under ROC curve was 0.870 ( 95 ％ CI:0.782 - 0.957,P ＜ 0.05 ).In concurrent chemoradiotherapy group,multivariate analysis showed that V35 and chemotherapy regimens during radiotherapy were risk factors of grade 2/3 ARE.The cut-off point of V35 was 23.75 while the area under ROC curve was 0.782 (95％ CI:0.636 -0.927,P ＜0.05).Vinorelbine and cisplatin regimen showed low incidence of ARE contrast with gemcitabine/docetaxel and cisplatin regimens (33.3％ and 66.7％ ).Conclusions V55 is the only statistically significant risk factor associated with grade 2 or worse ARE for patients who don't accepted concurrent chemotherapy.V35 and chemotherapy regimens during radiotherapy are statistically significant risk factors associated with grade 2 or worse ARE for patients who accept concurrent chemotherapy.Vinorelbine and cisplatin regimen during radiotherapy shows low incidence of ARE.